Pharmaceutical

MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset

MSD (Merck & Co) plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2.

Jul 14, 2024 - 04:00
MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
MSD (Merck & Co) plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2.
Read the original article

Tags:

Previous Article

Crossject secures funding from French Government for needle-free platform

Next Article

Explainer: Labour has been elected in the UK – now what?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How a ‘weighted lottery’ helped underserved patients get a scarce Covid drug

How a ‘weighted lottery’ helped underserved patients ge...

Sep 2, 2023

Novo Nordisk Foundation sets up airborne infection vaccine initiative

Novo Nordisk Foundation sets up airborne infection vacc...

Dec 18, 2023

STAT+: ‘Doctors need to get on top of this’: GPT-4 displays bias in medical tasks

STAT+: ‘Doctors need to get on top of this’: GPT-4 disp...

Jul 18, 2023